Category Archives: Induced Pluripotent Stem Cells


The integrated stress response: From mechanism to disease – Science Magazine

Proteostasis dISRupted

Despite their importance, many crucial networks for protein quality control within cells diminish with age. The resulting loss of proteostasis, the process by which the health of a cell's proteins is monitored and maintained, is associated with a wide range of age-related human diseases. Costa-Mattioli and Walter review the integrated stress response (ISR), a central signaling network that responds to proteostasis defects by tuning protein synthesis. The ISR is activated in a wide range of pathological conditions, so a mechanistic understanding of its pathway may help in the development of therapeutic tools through which it can be modulated.

Science, this issue p. eaat5314

The integrated stress response (ISR) is an evolutionarily conserved intracellular signaling network that helps the cell, tissue, and organism to adapt to a variable environment and maintain health. In response to different environmental and pathological conditions, including protein homeostasis (proteostasis) defects, nutrient deprivation, viral infection, and oxidative stress, the ISR restores balance by reprogramming gene expression. The various stresses are sensed by four specialized kinases (PERK, GCN2, PKR and HRI) that converge on phosphorylation of a single serine on the eukaryotic translation initiation factor eIF2. eIF2 phosphorylation blocks the action of eIF2s guanine nucleotide exchange factor termed eIF2B, resulting in a general reduction in protein synthesis. Paradoxically, phosphorylation of eIF2 also triggers the translation of specific mRNAs, including key transcription factors, such as ATF4. These mRNAs contain short inhibitory upstream open reading frames in their 5-untranslated regions that prevent translation initiation at their canonical AUGs. By tuning down general mRNA translation and up-regulating the synthesis of a few proteins that drive a new transcriptional program, the ISR aims to maintain or reestablish physiological homeostasis. However, if the stress cannot be mitigated, the ISR triggers apoptosis to eliminate the damaged cell.

Our understanding of the central mechanisms that govern the ISR has advanced vastly. The ISRs central regulatory hub lies in the eIF2eIF2B complex, which controls the formation of the eIF2GTPmethionyl-intiator tRNA ternary complex (TC), a prerequisite for initiating new protein synthesis. Assembly of functional TC is inhibited by eIF2-P, which blocks eIF2B noncompetitively. In mammalian cells, the phosphorylation of eIF2 is a tightly regulated process. In addition to the four specialized eIF2 kinases that phosphorylate eIF2, two dedicated phosphatases antagonize this reaction. Both phosphatases contain a common catalytic core subunit, the protein phosphatase 1 (PP1), and a regulatory subunit (GADD34 or CReP), which render the phosphatase specific to eIF2. Structural and biophysical approaches have elucidated the mechanism of action of eIF2B and its modulation by ISR inhibitors and activators. Gene expression analyses have revealed complex ISR-driven reprogramming. Although it has been long recognized that, in the brain, long-term memory formation requires new protein synthesis, recent causal and convergent evidence across different species and model systems has shown that the ISR serves as a universal regulator of this process. Briefly, inhibition of the ISR enhances long-term memory formation, whereas activation of the ISR prevents it. Consistent with this notion, unbiased genome-wide association studies have identified mutations in key components of the ISR in humans with intellectual disability. Furthermore, age-related cognitive disorders are commonly associated with the activation of the ISR. Most notably, oxidative stress, misfolded proteins, and other stressors induce the ISR in several neurodegenerative disorders, including Alzheimers disease. Recent genetic and pharmacological evidence suggest that tuning the ISR reverses cognitive dysfunction as well as neurodegeneration in a wide range of memory disorders that result from protein homeostasis defects. Thus, long-term memory deficits may primarily result as a consequence of ISR activation rather than from the particular proteostasis defects that lead to its induction. Finally, the ISR is also implicated in the pathogenesis of a plethora of other complex diseases, including cancer, diabetes, and metabolic disorders.

The ISR is emerging as a central regulator of protein homeostasis at both the cellular and organismal level. Mechanistically, much remains to be understood regarding additional inputs into the eIF2BeIF2 regulatory hub controlling TC concentration, as well as the IRSs connectivity to other intracellular signaling networks. As yet, little is known about the role of the specific proteins whose synthesis is altered during acute and persistent ISR activation and how these effectors collaborate to compute the life or death decisions cells make upon ISR activation. ISR gene expression signatures and functional consequences will need to be mapped across different tissues, cell types, and developmental stages. In addition, it will be invaluable to generate additional genetic and molecular tools that permit the direct temporal and spatial manipulation of ISR pathway in specific cells and circuits to determine their function. From a medical perspective, the ISR is implicated in the etiology of several disorders, and manipulation of the ISR is emerging as a promising therapeutic avenue for the treatment of a variety of diseases. The use of innovative mouse models, patient-derived induced pluripotent stem cells, and human organoids will greatly enhance our ability to explore the ISRs clinical relevance further and help define therapeutic windows in which ISR modulation may prove beneficial. Identifying additional specific small-molecule inhibitors and activators of the ISR will offer valuable opportunities to dissect the role of the ISR pharmacologically in health and disease. Finally, discovery and mechanistic understanding of additional ISR modulators will increase the repertoire of therapeutic targets and may further enable clinical development in a wide range of age-related human diseases.

Diverse deviations from homeostasis activate the ISR. The resulting dysregulation of translation contributes to numerous diseases.

Protein quality control is essential for the proper function of cells and the organisms that they make up. The resulting loss of proteostasis, the processes by which the health of the cells proteins is monitored and maintained at homeostasis, is associated with a wide range of age-related human diseases. Here, we highlight how the integrated stress response (ISR), a central signaling network that responds to proteostasis defects by tuning protein synthesis rates, impedes the formation of long-term memory. In addition, we address how dysregulated ISR signaling contributes to the pathogenesis of complex diseases, including cognitive disorders, neurodegeneration, cancer, diabetes, and metabolic disorders. The development of tools through which the ISR can be modulated promises to uncover new avenues to diminish pathologies resulting from it for clinical benefit.

See original here:
The integrated stress response: From mechanism to disease - Science Magazine

Diabetes reversed in mice with genetically edited stem cells derived from patients – Washington University School of Medicine in St. Louis

Visit the News Hub

CRISPR corrects genetic defect so cells can normalize blood sugar

Researchers at Washington University School of Medicine in St. Louis have transformed stem cells into insulin-producing cells. They used the CRISPR gene-editing tool to correct a defect that caused a form of diabetes, and implanted the cells into mice to reverse diabetes in the animals. Shown is a microscopic image of insulin-secreting beta cells (insulin is green) that were made from stem cells produced from the skin of a patient with Wolfram syndrome.

Using induced pluripotent stem cells produced from the skin of a patient with a rare, genetic form of insulin-dependent diabetes called Wolfram syndrome, researchers transformed the human stem cells into insulin-producing cells and used the gene-editing tool CRISPR-Cas9 to correct a genetic defect that had caused the syndrome. They then implanted the cells into lab mice and cured the unrelenting diabetes in those mice.

The findings, from researchers at Washington University School of Medicine in St. Louis, suggest the CRISPR-Cas9 technique may hold promise as a treatment for diabetes, particularly the forms caused by a single gene mutation, and it also may be useful one day in some patients with the more common forms of diabetes, such as type 1 and type 2.

The study is published online April 22 in the journal Science Translational Medicine.

Patients with Wolfram syndrome develop diabetes during childhood or adolescence and quickly require insulin-replacement therapy, requiring insulin injections multiple times each day. Most go on to develop problems with vision and balance, as well as other issues, and in many patients, the syndrome contributes to an early death.

This is the first time CRISPR has been used to fix a patients diabetes-causing genetic defect and successfully reverse diabetes, said co-senior investigator Jeffrey R. Millman, PhD, an assistant professor of medicine and of biomedical engineering at Washington University. For this study, we used cells from a patient with Wolfram syndrome because, conceptually, we knew it would be easier to correct a defect caused by a single gene. But we see this as a stepping stone toward applying gene therapy to a broader population of patients with diabetes.

Wolfram syndrome is caused by mutations to a single gene, providing the researchers an opportunity to determine whether combining stem cell technology with CRISPR to correct the genetic error also might correct the diabetes caused by the mutation.

A few years ago, Millman and his colleagues discovered how to convert human stem cells into pancreatic beta cells. When such cells encounter blood sugar, they secrete insulin. Recently, those same researchers developed a new technique to more efficiently convert human stem cells into beta cells that are considerably better at controlling blood sugar.

In this study, they took the additional steps of deriving these cells from patients and using the CRISPR-Cas9 gene-editing tool on those cells to correct a mutation to the gene that causes Wolfram syndrome (WFS1). Then, the researchers compared the gene-edited cells to insulin-secreting beta cells from the same batch of stem cells that had not undergone editing with CRISPR.

In the test tube and in mice with a severe form of diabetes, the newly grown beta cells that were edited with CRISPR more efficiently secreted insulin in response to glucose. Diabetes disappeared quickly in mice with the CRISPR-edited cells implanted beneath the skin, and the animals blood sugar levels remained in normal range for the entire six months they were monitored. Animals receiving unedited beta cells remained diabetic. Their newly implanted beta cells could produce insulin, just not enough to reverse their diabetes.

We basically were able to use these cells to cure the problem, making normal beta cells by correcting this mutation, said co-senior investigator Fumihiko Urano, MD, PhD, the Samuel E. Schechter Professor of Medicine and a professor of pathology and immunology. Its a proof of concept demonstrating that correcting gene defects that cause or contribute to diabetes in this case, in the Wolfram syndrome gene we can make beta cells that more effectively control blood sugar. Its also possible that by correcting the genetic defects in these cells, we may correct other problems Wolfram syndrome patients experience, such as visual impairment and neurodegeneration.

In the future, using CRISPR to correct certain mutations in beta cells may help patients whose diabetes is the result of multiple genetic and environmental factors, such as type 1, caused by an autoimmune process that destroys beta cells, and type 2, which is closely linked to obesity and a systemic process called insulin resistance.

Were excited about the fact that we were able to combine these two technologies growing beta cells from induced pluripotent stem cells and using CRISPR to correct genetic defects, Millman said. In fact, we found that corrected beta cells were indistinguishable from beta cells made from the stem cells of healthy people without diabetes.

Moving forward, the process of making beta cells from stem cells should get easier, the researchers said. For example, the scientists have developed less intrusive methods, making induced pluripotent stem cells from blood and they are working on developing stem cells from urine samples.

In the future, Urano said, we may be able to take a few milliliters of urine from a patient, make stem cells that we then can grow into beta cells, correct mutations in those cells with CRISPR, transplant them back into the patient, and cure their diabetes in our clinic. Genetic testing in patients with diabetes will guide us to identify genes that should be corrected, which will lead to a personalized regenerative gene therapy.

Maxwell KG, Augsornworawat P, Velazco-Cruz L, Kim MH, Asada R, Hogrebe NJ, Morikawa S, Urano F, Millman JR. Gene-edited human stem cell-derived cells from a patient with monogenic diabetes reverse pre-existing diabetes in mice. Science Translational Medicine, published online April 22, 2020.

This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of General Medical Sciences, the National Cancer Institute and the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). Grant numbers R01 DK114233, DK112921, TR002065, TR002345, T32 DK108742, R25 GM103757, T32 DK007120, P30 DK020579, P30 CA91842, UL1 TR000448 and UL1 TR002345. Additional assistance was provided by the Washington University Genome Engineering and iPSC Center, the Washington University Diabetes Center, and the Washington University Institute of Clnical and Translational Science, with additional funding from the JDRF, the Washington University Center of Regenerative Medicine, startup funds from the Washington University School of Medicine Department of Medicine, the Unravel Wolfram Syndrome Fund, Silberman Fund, Stowe Fund, Ellie White Foundation for Rare Genetic Disorders, Eye Hope Foundation, Snow Foundation, Feiock Fund, Childrens Discovery Institute, Manpei Suzuki Diabetes Foundation, and a JSPS Overseas Research Fellowship.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Originally posted here:
Diabetes reversed in mice with genetically edited stem cells derived from patients - Washington University School of Medicine in St. Louis

Business News: Induced Pluripotent Stem Cells Market Growth, Analysis and Forecast 2020 to 2025 | BlueRock Therapeutics, Corning Life Sciences, EMD…

Chicago, United States: The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the globalInduced Pluripotent Stem CellsMarket. It includes Porters Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Induced Pluripotent Stem Cells Market. We have provided deep analysis of the vendor landscape to give you a complete picture of current and future competitive scenarios of the global Induced Pluripotent Stem Cells market. Our analysts use the latest primary and secondary research techniques and tools to prepare comprehensive and accurate market research reports.

Top Key players cited in the report: BlueRock Therapeutics, Corning Life Sciences, EMD Millipore, Lonza Group, Promega, Thermo Fisher Scientific,

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart)

Each segment of the global Induced Pluripotent Stem Cells market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Induced Pluripotent Stem Cells market through leading segments. The regional study of the global Induced Pluripotent Stem Cells market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Induced Pluripotent Stem Cells market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Induced Pluripotent Stem Cells Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Induced Pluripotent Stem Cells market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Induced Pluripotent Stem Cells market participants in the past few years to remain ahead of the competition.

Global Induced Pluripotent Stem Cells Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Induced Pluripotent Stem Cells market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Induced Pluripotent Stem Cells market.

The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Request For Customization @ https://www.reporthive.com/request_customization/2278442

Report Highlights

Comprehensive pricing analysis on the basis of product, application, and regional segments

The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the global Induced Pluripotent Stem Cells market

Deep insights about regulatory and investment scenarios of the global Induced Pluripotent Stem Cells market

Analysis of market effect factors and their impact on the forecast and outlook of the global Induced Pluripotent Stem Cells market

A roadmap of growth opportunities available in the global Induced Pluripotent Stem Cells market with the identification of key factors

The exhaustive analysis of various trends of the global Induced Pluripotent Stem Cells market to help identify market developments

Table of Contents

Report Overview:It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Induced Pluripotent Stem Cells market segments by application, study objectives, and years considered.

Global Growth Trends:There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Induced Pluripotent Stem Cells Market Share by Manufacturer:Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type:It includes analysis of price, production value market share, and production market share by type.

Market Size by Application:This section includes Induced Pluripotent Stem Cells market consumption analysis by application.

Profiles of Manufacturers:Here, leading players of the global Induced Pluripotent Stem Cells market are studied based on sales area, key products, gross margin, revenue, price, and production.

Induced Pluripotent Stem Cells Market Value Chain and Sales Channel Analysis:It includes customer, distributor, Induced Pluripotent Stem Cells market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2232105

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Read the rest here:
Business News: Induced Pluripotent Stem Cells Market Growth, Analysis and Forecast 2020 to 2025 | BlueRock Therapeutics, Corning Life Sciences, EMD...

Stem Cell Therapy Market: Industry Size, Market Status, Influencing Factors, Competition, Outlook & Forecasts to 2027 – Cole of Duty

According to The Insight Partners market research study of Stem Cell Therapy Market to 2027 Global Analysis and Forecasts by Type, Treatment, Application, and End User. The global stem cell therapy market is expected to reach US$ 5,129.66 Mn in 2027 from US$ 1,534.55 Mn in 2019. The market is estimated to grow with a CAGR of 16.7% from 2020-2027. The report provides trends prevailing in the global stem cell therapy market and the factors driving market along with those that act as hindrances.

The global stem cell therapy market, based on the type, is segmented into adult stem cell, induced pluripotent stem cells, embryonic stem cell, and other stem cells. Adult stem cell therapy is further segmented into hematopoietic stem cells, mesenchymal stem cells, neuronal stem cells, and umbilical cord stem cells. The adult stem cell segment held the largest share of the market in 2019. The same segment is estimated to register the highest CAGR in the market during the forecast period due to its effectiveness for the treatment of chronic conditions coupled with higher compatibility with immunity system. The end user segment is segmented into academic and research institutes and hospitals & specialty clinics.

Request Sample Copy of this Report: https://www.theinsightpartners.com/sample/TIPHE100000991/

Major Key Players:

The report studies established names and emerging startups in the industry, to give the flavor of the entire business canvas. Different case studies from industry experts and policymakers have been mentioned for a clear understanding of the Global Stem Cell Therapy Market. It also offers comprehensive information on the product or service portfolio. All these factors which are studied in this research report are predicted to propel the Global Stem Cell Therapy Market.

Purchase This Report @ https://www.theinsightpartners.com/buy/TIPHE100000991/

Finally, all aspects of the Global Stem Cell Therapy Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects. The report supplies the international economic competition with the assistance of Porters Five Forces Analysis and SWOT Analysis.

Following are the List of Chapter Covers in the Global Stem Cell Therapy Market:

About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Here is the original post:
Stem Cell Therapy Market: Industry Size, Market Status, Influencing Factors, Competition, Outlook & Forecasts to 2027 - Cole of Duty

Induced Pluripotent Stem Cells Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Surfacing Magazine

DataIntelo report titled Global Induced Pluripotent Stem Cells Market provides detailed information and overview about the key influential factors required to make well informed business decision. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides latest insights about the markets drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Request Free Sample Report of Induced Pluripotent Stem Cells Market Report @ https://dataintelo.com/request-sample/?reportId=77310

Induced Pluripotent Stem Cells Market Report Includes:

For More Information on This Report Visit @ https://dataintelo.com/enquiry-before-buying/?reportId=77310

By Product Types:HepatocytesFibroblastsKeratinocytesAmniotic CellsOthers

The report is further broken down into various segments such as product types, applications, and regions.

By Applications:Academic ResearchDrug Development And DiscoveryToxicity ScreeningRegenerative Medicine

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

The Induced Pluripotent Stem Cells Market Report Covers the Following Companies:Fujifilm Holding CorporationAstellas PharmaFate TherapeuticsBristol-Myers Squibb CompanyViaCyteCelgene CorporationAastrom BiosciencesAcelity HoldingsStemCellsJapan Tissue EngineeringOrganogenesis

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants understand the competitive scenario to plan future strategies.

To Purchase This Report: https://dataintelo.com/checkout/?reportId=77310

The Report Provides:

The Induced Pluripotent Stem Cells Market Report Addresses the Following Queries:

For Best Discount on Purchasing this Report Visit https://dataintelo.com/ask-for-discount/?reportId=77310

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: sales@dataintelo.comWebsite: https://dataintelo.com

Read more:
Induced Pluripotent Stem Cells Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Surfacing Magazine

Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 – WhaTech Technology and Markets News

Induced Pluripotent Stem Cells Market research report provides the details about Industry Chain structure, Market Competition, Market Size & Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development & Trends, Regional Forecast, Company & Profile, and Product & Service.

This Induced Pluripotent Stem Cells Market research report is focused on providing its reader with all the necessary details that can help them make necessary business decisions. It provides wholesome information that is necessary to understand the market inside-out.

ReportsnReports has recently added a new research report to its expanding repository. The research report, titled Induced Pluripotent Stem Cells Market, mainly includes a detailed segmentation of this sector, which is expected to generate massive returns by the end of the forecast period, thus showing an appreciable rate of growth over the coming years on an annual basis.

The research study also looks specifically at the need for Induced Pluripotent Stem Cells Market.

Download A Sample Report atwww.reportsnreports.com/contactme=2906851

Report Scope:

This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered.

For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelia cells and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of the World.

Research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.

Report Includes:

59 tables

An overview of the global market for induced pluripotent stem cells

Analyses of global market trends with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024

Information on induced pluripotent stem cell research products, including various assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes

Complete understanding of the key technologies adopted for induced pluripotent stem cell research

Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth

Profiles of major players in the industry, including Applied StemCell Inc., BlueRock Therapeutics, Corning Life Sciences, EMD Millipore, Lonza Group Ltd., Promega Corp. and Thermo Fisher Scientific Inc.

Summary

It has been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology. The market has gradually become an important part of the life sciences industry during recent years.

Particularly for the past five years, the global market for iPSCs has experienced a rapid growth. The market was estimated at REDACTED in 2018 and over REDACTED in 2019, with an average REDACTED growth.

The overall iPSC market is forecast to continue its steady growth and reach REDACTED in 2024, with anestimated compound annual growth rate (CAGR) of REDACTED from 2019 through 2024.

Key Drivers for Market Growth

This report has identified several key drivers for the rapidly growing market

iPSCs hold promising hope for therapeutic solutions for diseases without ethical issues. A series of technical breakthroughs were made in recent years for improving cellular reprogramming, differentiation and large-scale production of GMP- grade iPSCs derived cells toward clinical usability.

Advances in genetics such as NGS technologies have promoted the progress on precision medicine, where the availability of iPSCs from a variety of genetic, lifestyle and environment backgrounds will help make the precision healthcare a clinical reality. iPSC banking together with related technologies is developing into a platform for precision and personalized medicine, which is experiencing rapid growth globally.

In recent years, several iPSCs clinical trials have been or are going to be launched for a variety of diseases. The first human iPSC clinical trial started in August 2014, and the recent report of the first macular degeneration patient treated with the sheets of retinal pigmented epithelial cells made from iPSCs was encouraging.

The progresses toward clinical practice will drive the growth of the clinical market and the research market as well.

The pharmaceutical industry needs better cell sources such as iPSC-derived functional cells for drug toxicity testing and drug screening.

The U.S. government has been encouraging the marketing of stem cells, including iPSCs.

The U.S. Food and Drug Administration (FDA) has been authorized to provide orphan drug designations for many of the therapies developed for rare diseases such as Parkinsons and Huntingtons using stem cells.

The provisions of grants from organizations, such as the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) have been encouraging for the research institutes to venture into iPSC research.

Rapidly growing medical tourism and contract research outsourcing drives the Asia-Pacific stem cell market.

Cellular reprogramming, including iPSC technology, was awarded the 2012 Nobel Prize.

New biotechnologies such as CRISPR/Cas genome editing technology are advancing iPSCs into more and better uses. For example, the hypoimmunogenic derivatives of engineered iPSCs have shown lost immunogenicity which would become a potential novel therapy to treat various diseases.

Please Share Your Specific Interest To Serve You Better | Download PDF Brochure atwww.reportsnreports.com/contactme=2906851

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Induced Pluripotent Stem Cells Market. Different strategies implemented by these vendors have been analyzed and studied in order to gain a competitive edge, create unique product portfolios and increase their market share.

The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players.

In addition, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

Scope of the Report:

Through following the Induced Pluripotent Stem Cells Market through depth, the readers should find this study very helpful. The aspects and details are depicted by charts, bar graphs, pie diagrams, and other visual representations in theInduced Pluripotent Stem Cells Market study.

This intensifies the representation of the pictures and also helps to improve the facts of the Induced Pluripotent Stem Cells Market industry. At a substantial CAGR, the Induced Pluripotent Stem Cells Market is likely to grow.

Induced Pluripotent Stem Cells Market reports main objective is to guide the user to understand the market in terms of its definition, classification, industry potential, the latest trends, and the challenges facing the Induced Pluripotent Stem Cells Market.

Access Full Report atwww.reportsnreports.com/purchasme=2906851

And More

This email address is being protected from spambots. You need JavaScript enabled to view it.

Original post:
Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 - WhaTech Technology and Markets News

Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production – ENGINEERING.com

Parker Hannifin has sponsored this post.

Cell therapies promise treatments for serious illnesses, but require automation and manufacturing expertise to scale up production for research and products. (Image courtesy of Parker Hannifin.)

Cellular therapies and bio-fabrication are two of the most revolutionary treatments for serious illnesses to be developed in the early 21st century, offering the hope of cures where once only symptomatic treatments were available. The 2006 discovery of Induced Pluripotent Stem Cells (iPSCs) formed a catalyst for research and development into these new therapeutic approaches. Stem cell therapies offer promising avenues for the treatment of devastating illnesses such as diabetes, cancer, heart disease and even neurological diseases.

Tailored cell therapies using iPSCs are considered to be the new Third Pillar of the drug and treatment industry, standing alongside small molecules and biologics as tools for treatment. However, the widespread research and treatment using cell therapies requires mass-produced iPSCs to be available in quantitywhich means advanced manufacturing techniques.

Cells are tiny living, complex organisms; they must be handled with precision and accuracy. Automated handling equipment needs a heightened level of dexterity and control. (Image courtesy of Parker Hannifin.)

Scaling up the production of iPSCs requires investmentsome of which is already in place with two deals: $70 million to the New Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to advance U.S. leadership in the biopharmaceutical industry, and an 87-member coalition funded by the Defense Department called ARMI-BioFab USA, which aims to develop the next-generation techniques needed to repair and replace cells, tissues and organs for wounded military service veterans.

The key to success in the scale-up of production is advanced automation, which will improve the manufacturing process used to fabricate cell colonies.

Currently, most research and cell fabrication involves a significant amount of manual work and decision-making, which can be error-prone and represents a bottleneck in attempts to scale these fabrication processes.

One way to improve the manufacturing processes related to cell therapies is by partnering with experienced automation and manufacturing industry leaders, who can share their expertise. An example of this is the partnership between Parker Hannifin and CellX Technologies. Together, these companies have developed a platform to help researchers and clinicians quantify key morphological stem cells, automate the handling process and perform cell maintenance.

Current cell therapy research is hampered by difficulties with a lack of large field-of-view and high-resolution optics when imaging live cell cultures. This makes it difficult to monitor and quantify changes to the cells. Available devices and equipment for sampling, transfer or deletion of specific cells or colonies also lack the rigorous accuracy that manufacturing-scale production would require. Instead, visual assessment and manual transfer by lab technicians is the usual methodsacrificing speed and production volume.

An automated, image-based system would enable accurate quantitative metrics of biological performance and will be applicable at a cell-by-cell or a colony-by-colony basis, among other benefits.

Automated cell-handling equipment needs to be precise and finely calibrated in order to handle delicate cells with the necessary dexterity and control. Three primary handling techniques are used for this very difficult automation task:

Combining capabilities for these three functions into a single platform will enable multiple benefits, including improved reproducibility and quality of cells for research and products, reduce variability and costs from manual processes, improved lot traceability and documentation, and define quantitative process quality attributes and metrics.

Parker Hannifins expertise in manufacturability, digital pathology and additive manufacturing lends itself directly to the development of the CellX platform. CellX enables automation of the scanning and identification processes, and pairs this with cell selection and precision placement.

The CellX Device, developed by Parker Hannifin and CellX Technologies, combines large field-of-view imaging with precision instrumentation, fluidics, and documentation and control capabilities. (Image courtesy of Parker Hannifin.)

CellX also needed customization of standard products. Parker Hannifin has decades of experience in close tolerance special purpose fluidics and actuator technology, and developed enabling technology for the CellX central core, which consists of a high-quality automated inverted microscope and CCD camera with brightfield and fluorescent imaging capabilities.

Some of the specialized equipment that Parker Hannifin helped develop for CellX includes a load and removal station for disposable cell-picking tips, and environmentally controlled workspace to maintain sterility and oxygen levels, and an integrated sensor to accurately locate each new tip.

The combined precision and imaging capabilities of the CellX platform enable rapid data collection and high repeatability, which means researchers can rely on accurate data, healthy cell colonies and quantitative, reproducible standards for cell therapy development. Parker Hannifin has a proven history of developing new tools and instruments for manufacturing processes with their partner OEMsand in the case of CellX, accelerating the development of the future of cell therapies.

To learn more about Parker Hannifins development of the CellX platform, including use cases and details on the full complement of customized equipment and enabling features, download the full whitepaper from Parker Hannifin.

See more here:
Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production - ENGINEERING.com

Lung epithelium model being tested as a platform for COVID-19 research – Drug Target Review

The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.

A biotech company has announced they are testing whether their human lung epithelium model could be used as a platform for investigating SARS-CoV-2 infection and developing and evaluating potential antiviral strategies for COVID-19.

Newcells Biotech based their lung epithelium organoid on human induced pluripotent stem cells (hiPSC) and have been developing the model for two years. The model contains basal epithelia, ciliated and secretory cells (goblet and club cells) organised in a stratified epithelium. The company stated it has already confirmed it expresses the mRNA for the angiotensin converting enzyme (ACE2) which SARS-CoV, the coronavirus causing COVID-19, uses to infect cells. It is currently determining whether ACE2 is present on the surface of cells in the model.

Once this is confirmed, the enterprise intends to challenge the model with the virus to confirm it can infect and virally replicate. The company is working with two laboratories to design these protocols.

According to Newcells, before the COVID-19 pandemic it had been developing a hiPSC-derived model of the upper airway for toxicology testing of environmental pollutants. This model has been shown to respond to airborne particles with cytokine responses and changes in gene expression.

The enterprise said it is working rapidly to demonstrate the utility of its assays for COVID-19 research and is interested in working with collaborators.

Related topicsCell-based assays, Disease research, Drug Development, Drug Discovery, Drug Targets, Immunology, Organoids, Protein Expression, Proteomics, Research & Development, Stem Cells

Read more:
Lung epithelium model being tested as a platform for COVID-19 research - Drug Target Review

Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion – Clinical OMICs News

Johnson & Johnsons Janssen Biotech will partner with Fate Therapeutics to create cell-based cancer immunotherapies derived from induced pluripotent stem cells (iPSCs), through a collaboration that could generate more than $3 billion for the San Diego cellular immunotherapy developer.

Janssen will bring to the partnership its proprietary antigen binding domains, with the aim of creating product candidates for up to four tumor associated antigens for blood and solid cancers.

To create those candidates, Janssen plans to use Fates iPSC product platform to research and develop novel chimeric antigen receptor (CAR) natural killer (NK) and CAR T-cell product candidates to preclinical phases.

The iPSC platform is designed to enable mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments, according to Fate.

Fates platform involves engineering human iPSCs in a one-time genetic modification event, then selecting a single engineered iPSC for maintenance as a clonal master iPSC line. The company says its clonal master iPSC lines are a renewable source for manufacturing cell therapy products that are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment.

Fate said it will advance candidates created through the collaboration to the filing of an IND application, after which Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens.

Fate will have primary responsibility for manufacturing candidates created through the collaboration, with Janssen paying for their cost.

$50M upfront

Janssen agreed to pay Fate $50 million upfront, while another J&J entity, Johnson & Johnson InnovationJJDC, will purchase newly-issued shares of Fates common stock at a price per share of $31.00a 31% premium over Fates closing share price Friday of $22.94.

Janssen also agreed to pay Fate up to $1.8 billion in payments tied to achieving development and regulatory milestonesplus another up to $1.2 billion tied to achieving commercial milestones, as well as double-digit royalties on worldwide commercial sales of products targeting the antigens.

Fate has the right to elect to co-commercialize each collaboration candidate in the United States and share equally in profits and losses in the United States, subject to paying clinical development costs and adjustments in milestone and royalty payments.

Janssen also agreed to reimburse Fate for all activities conducted under the collaboration.

The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen binding domains, while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Fate president and CEO Scott Wolchko said Thursday in a statement.

Read more:
Fate Therapeutics' IO Collaboration with Janssen Could Yield Company $3 Billion - Clinical OMICs News

Induced Pluripotent Stem Cells Market Key Players, Size, Share, Growth, Trends, Analysis And Forecast 2025 – Science In Me

A report added to the rich database of Qurate Business Intelligence, titled Global Induced Pluripotent Stem Cells Market Size, Status and Forecast 2025, provides a 360-degree overview of the worldwide market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the data reliable in context to particular time period and industry.This report is highly informative document with inclusion of comprehensive market data associated with the significant elements and subdivision of the Global Induced Pluripotent Stem Cells Market that may impact the growth scenarios of the industry. The report may commendably help trades and decision makers to address the challenges and to gain benefits from highly competitive Global Induced Pluripotent Stem Cells Market

Get Free Sample Copy of This [emailprotected]https://www.qurateresearch.com/report/sample/ICT/global-induced-pluripotent-stem-cells-market/QBI-MMR-ICT-592258

A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.

The major players profiled in this report include:

Fujifilm Holding Corporation (CDI)NcardiaSumitomo Dainippon PharmaAstellas Pharma IncFate Therapeutics, IncPluricell BiotechCell Inspire BiotechnologyReproCELL

Major types in global Induced Pluripotent Stem Cells market includes:Human iPSCsMouse iPSCs

Major application in global Induced Pluripotent Stem Cells market includes:Academic ResearchDrug Development and DiscoveryToxicity ScreeningRegenerative MedicineOthers

Global Induced Pluripotent Stem Cells Market is research report of comprehensive nature which entails information in relation with major regional markets, current scenarios. This includes key regional areas such as North America, Europe, Asia-Pacific, etc. and the foremost countries such as United States, Germany, United Kingdom, Japan, South Korea and China.

The Global Induced Pluripotent Stem Cells Market report attempts to build familiarity of the market through sharing basic information associated with the aspects such as definitions, classifications, applications and market overview, product specifications, manufacturing processes, cost structures, raw materials and more. Furthermore, it strives to analyze the crucial regional markets, including the product price, profit, capacity, production, supply, demand and market growth rate. It also discusses forecast for the same. The report concludes with new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Do You Have Any Query? Ask to Our Industry [emailprotected]https://www.qurateresearch.com/report/enquiry/ICT/global-induced-pluripotent-stem-cells-market/QBI-MMR-ICT-592258

In addition, this report identifies pin-point analysis of competitive dashboard and helps readers to develop competitive edge over others. It delivers a noteworthy data and insights associated with factors driving or preventing the growth of the market. It brings a nine-year forecast evaluated on the basis of how the market is expected to perform.

It assists readers in understanding the key product sections and their future. Its counsels in taking well-versed business decisions by giving complete intuitions of the market and by forming a comprehensive analysis of market subdivisions. To sum up, it also provides confident graphics and personalized SWOT analysis of foremost market subdivisions.This statistical surveying report presents comprehensive assessment of the global market for Induced Pluripotent Stem Cells, discussing several market verticals such as the production capacity, product pricing, the dynamics of demand and supply, sales volume, revenue, growth rate and more.

Buy Complete [emailprotected]https://www.qurateresearch.com/report/buy/ICT/global-induced-pluripotent-stem-cells-market/QBI-MMR-ICT-592258

Table of Content:

Global Global Induced Pluripotent Stem Cells Market Research Report 2020-2025

Chapter 1: Industry Overview

Chapter 2: Induced Pluripotent Stem Cells International and China Market Analysis

Chapter 3: Environment Analysis of Induced Pluripotent Stem Cells

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Revenue by Regions and Applications

Chapter 6: Analysis of Induced Pluripotent Stem Cells Revenue Market Status.

Chapter 7: Analysis of Induced Pluripotent Stem Cells Industry Key Manufacturers

Chapter 8: Sales Price and Gross Margin Analysis

Chapter 9: Marketing Trader or Distributor Analysis of Induced Pluripotent Stem Cells Market

Chapter 10: Development Trend of Induced Pluripotent Stem Cells Industry 2020-2025

Chapter 11: Industry Chain Suppliers of Induced Pluripotent Stem Cells with Contact Information

Chapter 12: New Project Investment Feasibility Analysis of Induced Pluripotent Stem Cells

Chapter 13: Conclusion of the Global Induced Pluripotent Stem Cells Market Research Report

Web: http://www.qurateresearch.comE-mail: [emailprotected]Ph: US +13393375221

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Qurate Business Intelligence delivers unique Market research solutions to its customers and help them to get equipped with refined information and Market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Read the rest here:
Induced Pluripotent Stem Cells Market Key Players, Size, Share, Growth, Trends, Analysis And Forecast 2025 - Science In Me